Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Narayana Hrudayalaya...

    Narayana Hrudayalaya Q2 FY18 Consolidated operating income at Rs 5,592 million

    Written by Ruby Khatun Khatun Published On 2017-11-08T10:07:11+05:30  |  Updated On 8 Nov 2017 10:07 AM IST
    Narayana Hrudayalaya Q2 FY18 Consolidated operating income at Rs 5,592 million

    Bengaluru: Narayana Hrudayalaya Limited, a leading healthcare service provider in India, announced its financial results for the second quarter (Q2 FY18) and six months (H1 FY18) ended September 30th, 2017.


    Financial Highlights for the Quarter (Q2 FY18) - Prepared in accordance with Ind AS (‘Indian Accounting Standards’)


    ▪ Consolidated total operating income was Rs 5,592 mn for Q2 FY18 as compared to Rs 4,874 mn in the corresponding period of the previous year, reflecting an increase of 14.7%


    ▪ Consolidated EBITDA stood at Rs 638 mn, reflecting a margin of 11.4% as against Rs 681 mn in Q2 FY17


    ▪ PAT after minority interest and share of loss in associates stood at Rs 165 mn as compared to Rs 265 mn in Q2 FY17


    Financial Highlights for the Six Months (H1 FY18)


    ▪ Consolidated total operating income was Rs 10,803 mn for H1 FY18 as compared to Rs 9,394 mn in the corresponding period of the previous year, reflecting an increase of 15.0%


    ▪ Consolidated EBITDA stood at Rs 1,194 mn, reflecting a margin of 11.1% as against Rs 1,240 mn in H1 FY17


    ▪ PAT after minority interest and share of loss in associates stood at Rs 275 mn as compared to Rs 437 mn in H1 FY17


    As on September 30th, 2017, the consolidated net debt was Rs 3,375 mn representing a net debt to equity ratio of 0.34


    Other Highlights of the Quarter


    ▪ The super speciality hospital at Vaishno Devi, Jammu performed its 5,000th dialysis in August 2017 (17th month of operations) cementing the facility’s pre-eminence in nephrology in the northern region of the country


    ▪ The hospital in Mumbai successfully performed Extracorporeal Membrane Oxygenation (ECMO) on a little girl suffering from H1N1 and severe hypoxemic respiratory failure, the procedure being first of its kind in a paediatric case in Mumbai


    ▪ For the first time in Eastern India, a patient was successfully treated with Flattering Filter-Free Radiotherapy in Narayana Superspeciality Hospital, Howrah bolstering our reputation as a leading player in oncology


    ▪ The hospital in Howrah successfully performed a complicated procedure involving Intra-Cardiac Repair for Tetralogy of Fallot along with a complete chest wall reconstruction of a 2-year-old girl


    ▪ NH won The Economic Times “The Best Asian Healthcare Brands 2017” award and “The Express Healthcare Excellence Award 2017” in Health Tourism category in September 2017


    ▪ The SRCC Children’s Hospital won “The Best Emerging Brand” award at the National Award for Marketing Excellence presented by Times Network in September 2017


    Commenting on the performance, Dr. Ashutosh Raghuvanshi, Vice Chairman, Managing Director and Group CEO, Narayana Hrudayalaya Limited, said “First quarter of fiscal 2018, despite being hit by regulatory challenges, witnessed a strong growth in revenues and we are pleased to report that the second quarter continued with the strong momentum generated in Q1 FY18. Results in this quarter are in accordance with our expectations taking into consideration the typical maturity cycle a newly commissioned hospital like our Mumbai facility experiences in its initial phase of operations. We remain confident about the long-term prospects of our business and committed towards the growth trajectory NH has charted upon.”

    EBITDAFinancial resultshospitalhospital indiaNarayana Hrudayalayanet profitsecond quarter
    Source : Press Release

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok